Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) shares traded up 4.1% during mid-day trading on Tuesday after Citigroup raised their price target on the stock from $16.00 to $17.00. Citigroup currently has a buy rating on the stock. Oric Pharmaceuticals traded as high as $7.95 and last traded at $7.8280. 116,932 shares traded hands during trading, a decline of 93% from the average daily volume of 1,706,746 shares. The stock had previously closed at $7.52.
A number of other research firms also recently issued reports on ORIC. BTIG Research reiterated a “buy” rating and issued a $26.00 price objective on shares of Oric Pharmaceuticals in a report on Tuesday. JPMorgan Chase & Co. boosted their price target on Oric Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Leerink Partners started coverage on Oric Pharmaceuticals in a research report on Monday, October 5th. They issued an “outperform” rating and a $26.00 price target on the stock. Stifel Nicolaus upped their price target on Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, October 26th. Finally, Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th. Fourteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Oric Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $21.33.
Check Out Our Latest Research Report on Oric Pharmaceuticals
Insiders Place Their Bets
Hedge Funds Weigh In On Oric Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Oric Pharmaceuticals during the second quarter valued at approximately $73,904,000. Siren L.L.C. grew its position in shares of Oric Pharmaceuticals by 197.6% during the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock valued at $37,987,000 after purchasing an additional 1,990,617 shares in the last quarter. Algert Global LLC increased its stake in Oric Pharmaceuticals by 791.3% in the 2nd quarter. Algert Global LLC now owns 1,215,293 shares of the company’s stock worth $13,162,000 after acquiring an additional 1,078,943 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Oric Pharmaceuticals during the 2nd quarter valued at approximately $11,675,000. Finally, Defilade Capital Management L.P. bought a new position in shares of Oric Pharmaceuticals during the 1st quarter valued at approximately $10,680,000. Hedge funds and other institutional investors own 95.05% of the company’s stock.
Oric Pharmaceuticals Stock Up 2.3%
The business’s fifty day moving average is $11.45 and its two-hundred day moving average is $10.99. The stock has a market capitalization of $797.07 million, a PE ratio of -5.68 and a beta of 1.23.
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.05). Sell-side analysts expect that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current fiscal year.
About Oric Pharmaceuticals
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Featured Stories
- Five stocks we like better than Oric Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
